Log In
Print
BCIQ
Print
Print this Print this
 

IDX21459

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionUridine-based nucleotide prodrug
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3,700.0M

$3,700.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today